Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a leading player in the animal health sector with a comprehensive industry chain and global perspective [1][3][5] Group 2 - Xinde Technology has established itself as a leader in the animal health industry, ranking among the top three in the core segment of avian veterinary biological products and holding a dominant position in several high-barrier niche markets [3][4] - The company has a strong research and development (R&D) platform, employing advanced technologies such as full suspension cell culture for producing high-pathogenic avian influenza vaccines, and has a team of 189 R&D personnel with over 60% holding master's degrees or higher [4] Group 3 - Financial performance has been robust, with a reported revenue of 877 million yuan for the first nine months of 2025, representing a year-on-year growth of 25.2%, and a pre-tax profit increase exceeding 100% [5] - The company's global strategy has led to explosive growth in overseas business, with overseas revenue reaching 46.1 million yuan, a year-on-year increase of 123.8% [5] Group 4 - The funds raised from the Hong Kong listing will be used to enhance R&D capabilities, expand advanced production capacity, and deepen global expansion efforts, with the goal of becoming a globally influential leader in animal health [7]